Molecular biomarkers for vascular cognitive impairment and dementia:the current status and directions for the future  

作　　者：Satoshi Hosoki Perminder SSachdev 

机构地区：[1]Centre for Healthy Brain Ageing,Discipline of Psychiatry and Mental Health,School of Clinical Medicine,Faculty of Medicine and Health,University of New South Wales,Sydney,Australia [2]Department of Neurology,National Cerebral and Cardiovascular Center,Osaka,Japan

出　　处：《Neural Regeneration Research》2024年第12期2579-2580,共2页中国神经再生研究（英文版）

基　　金：supported by the Japan Society for the Promotion of Science Overseas Research Fellow,the fellowship of Astellas Foundation for Research on Metabolic Disorders and the Japanese Society of Neurology grants for overseas study“Young Researcher Overseas Training Program” (SH)and NHMRC CRE grant 2006765 (to PSS)。

摘　　要：Dementia is a syndrome with various underlying pathologies acting independently or in concert to cause cognitive dysfunction.The development of disease-specific treatments and targeted prevention strategies requires precise clinical sub-typing via etiology and pathophysiological processes.Furthermore,recent research advances in biomarkers,especially for Alzheimer's disease(AD)diagnosis,have improved diagnostic precision for dementia.

关 键 词：PREVENTION DIAGNOSIS IMPAIRMENT 

分 类 号：R749.16[医药卫生—神经病学与精神病学]